Nika Pharmaceuticals Inc.
NIKA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $3,000 | $0 |
| G&A Expenses | $96 | $65 | $184 | $15 |
| SG&A Expenses | $96 | $65 | $184 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $96 | $65 | $3,184 | $15 |
| Operating Income | -$96 | -$65 | -$3,184 | -$15 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$96 | -$65 | -$3,184 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$96 | -$65 | -$3,184 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0 | -0 | -0.004 | 0 |
| % Growth | 0% | 97.2% | – | – |
| EPS Diluted | -0 | -0 | -0.004 | 0 |
| Weighted Avg Shares Out | 1,021,675 | 876,090 | 876,090 | 876,090 |
| Weighted Avg Shares Out Dil | 1,021,675 | 876,090 | 876,090 | 876,090 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$96 | -$65 | -$3,184 | -$15 |
| % Margin | – | – | – | – |